Kenvue Inc. (NYSE:KVUE) Shares Sold by Mcintyre Freedman & Flynn Investment Advisers Inc.

Mcintyre Freedman & Flynn Investment Advisers Inc. cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 36,654 shares of the company’s stock after selling 897 shares during the quarter. Mcintyre Freedman & Flynn Investment Advisers Inc.’s holdings in Kenvue were worth $666,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Manchester Capital Management LLC grew its stake in shares of Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the period. Mather Group LLC. acquired a new stake in Kenvue in the 1st quarter valued at about $28,000. MV Capital Management Inc. grew its stake in Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after acquiring an additional 642 shares during the last quarter. Salomon & Ludwin LLC acquired a new stake in Kenvue in the 1st quarter valued at about $33,000. Finally, Riverview Trust Co acquired a new stake in Kenvue in the 1st quarter valued at about $33,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Kenvue in a research note on Wednesday, August 7th. JPMorgan Chase & Co. raised their price target on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Citigroup decreased their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $21.44.

Kenvue Trading Up 1.3 %

NYSE KVUE opened at $23.39 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.47. The company’s 50 day moving average price is $20.41 and its 200 day moving average price is $19.81. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99. The firm has a market capitalization of $44.80 billion, a price-to-earnings ratio of 29.99, a PEG ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The firm had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. Kenvue’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 earnings per share. On average, sell-side analysts predict that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.